SNOA
Sonoma Pharmaceuticals, Inc. (SNOA) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Current ratio of 3.0 and quick ratio of 2.3 indicate liquidity above many small-cap peers, supporting near-term operating flexibility despite weak profitability.
Debt-to-equity of 0.11 suggests modest balance-sheet leverage versus more levered peers, which can reduce refinancing pressure and preserve optionality.
Cash conversion cycle of 96.5 days is manageable for a specialty industrial distributor, implying working-capital discipline relative to peers with longer inventory cycles.
Weaknesses
ROIC of -9.8% shows capital is not earning its cost, leaving SNOA structurally behind profitable peers on value creation.
Net debt to EBITDA of 2.9x is elevated for a company with negative returns, constraining flexibility versus peers with stronger earnings coverage.
Long cash conversion cycle of 96.5 days ties up cash in inventory and receivables, weakening liquidity efficiency relative to faster-turning peers.
Opportunities
If working capital turns improve, the 96.5-day cash conversion cycle offers room to release cash faster than peers with less inventory discipline.
Low debt-to-equity creates capacity to fund selective growth or restructuring without immediate balance-sheet strain, unlike more leveraged competitors.
Any return to positive invested-capital returns would have outsized peer-relative impact because the current negative ROIC leaves substantial operating headroom.
Threats
Persistent negative ROIC threatens competitive positioning because peers generating positive returns can reinvest faster and widen performance gaps over time.
High net debt to EBITDA increases vulnerability to earnings volatility, especially versus peers with cleaner leverage and stronger interest coverage.
Extended cash conversion cycle raises the risk of working-capital shocks, which can pressure liquidity more than in peers with shorter operating cycles.
Overall Score
SNOA’s peer positioning is weak overall because negative capital returns and elevated leverage outweigh its relatively solid liquidity and modest balance-sheet debt.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Sonoma Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
